The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: amiodarone     Quarter: 2016Q3

Total Drug/Injury Combinations: 610     Number of Pages: 31

DRUGNAME PT EventCount
AMIODARONE HCL Polyneuropathy 1 view events
AMIODARONE HCL Potentiating drug interaction 1 view events
AMIODARONE HCL Product taste abnormal 1 view events
AMIODARONE HCL Pyrexia 1 view events
AMIODARONE HCL Rash 1 view events
AMIODARONE HCL Respiratory disorder 1 view events
AMIODARONE HCL Respiratory tract infection 1 view events
Amiodarone hcl Restlessness 1 view events
AMIODARONE HCL Slow response to stimuli 1 view events
AMIODARONE HCL Somnolence 1 view events
AMIODARONE HCL Swollen tongue 1 view events
AMIODARONE HCL Thyroiditis 1 view events
AMIODARONE HCL Torsade de pointes 1 view events
AMIODARONE HCL Tremor 1 view events
AMIODARONE HCL Troponin I increased 1 view events
AMIODARONE HCL Umbilical haemorrhage 1 view events
AMIODARONE HCL Upper limb fracture 1 view events
AMIODARONE HCL Vascular occlusion 1 view events
AMIODARONE HCL Vasodilatation 1 view events
AMIODARONE HCL Ventricular extrasystoles 1 view events

Total Drug/Injury Combinations: 610     Number of Pages: 31

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)